Triple-Negative Breast Cancer (TNBC) Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02981303Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast CancerTreatment